The West Yorkshire, UK-based firm says the system runs from one cylinder of mixed gas and there are separate cycles to prepare anaerobic or microaerobic conditions. It takes less than two minutes and about 18p to create an anaerobic environment, and just 15 seconds and less than 3p to achieve microaerobic conditions.
According to the company, laboratories with low sample throughput can justify this system as a compact and cost-effective alternative to a workstation.
Using the Whitley jar gassing system also eliminates chemical waste and reduces condensation so that samples can be handled and read more easily following incubation, the company says.
Optional accessories include adaptor kits for reusing existing anaerobic jars.
Jar gassing system gains a colour touch screen
And an optional printer for traceability, auditing and accreditation
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Read morePrecise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?
